01What Part III Is — A Home for "Neither" Materials

The creation guide splits into three parts. Part I covers product information summaries; Part II covers advertisements placed in professional print journals. So how are materials that fit neither category governed? The answer is Part III, titled, fittingly, "Other Materials." Slides an MR uses to explain a product, proceedings of lectures and study meetings, posters and panels at academic venues, notices to medical institutions, disease-explanation pamphlets, patient medication-guidance leaflets, product lists, compatibility tables, congress abstract collections, journal reprints, literature digests — most of the paper and digital handed out in daily practice actually belongs here.

Part III is built from eleven chapters. The chapter breakdown is fine-grained by medium and use because materials with different characters demand different points of vigilance. A leaflet handed to a patient and an abstract collection released only on request to a medical professional invite entirely different kinds of deviation. So rather than throwing out one blanket principle and stopping there, the guide works out the specifics chapter by chapter.

Where Parts I and II handle "materials with a fixed form," Part III handles "materials that fall outside that form." As media expand from print toward digital and the Web, the materials sorted here keep multiplying. Part III is, in a sense, the guide's front line.

02How to Judge an Unspecified Material — The Foreword's Spirit Becomes the Operating Rule

Part III's defining feature is that it assumes, from the start, that "materials with no explicit provision here" will inevitably appear. Media evolve; new ways of presenting information arise one after another. The guide cannot list them all in advance. So is a material with no explicit rule free? No.

When there is no explicit provision, judge by returning to the intent of the product information summary and to the JPMA Code — this is Part III's operating rule. It translates into practice the very spirit of the foreword. The foreword made clear that the guide states basic matters and is not exhaustive, and that matters outside its provisions remain subject to the Pharmaceuticals and Medical Devices Act, the Standards for Fair Advertising, the guidelines for sales information provision activities, and the JPMA Code. Part III lowers that thinking one rung and forecloses the notion that "not in the manual = no answer = anything goes."

"It isn't written in the guide, so it's allowed" is the classic misreading. The very areas without explicit text are where you must govern yourself against the higher norms (the Act, the Standards for Fair Advertising, the JPMA Code) and against the "why" embodied in the product-summary intent. Using the guide as an answer key and hunting for loopholes is what is most cautioned against.

Why Send the Reader Back to "Intent"

A mindset of matching clauses one by one freezes the moment a situation has no matching clause. To keep thought from freezing there, the guide sets the purpose behind each prohibition — deliver accurate information to medical professionals, avoid creating misunderstanding, advance proper use — as the final point of reference for judgment. By showing a destination rather than a procedure, it stays able to handle unknown media.

03Three Threads Running Through Part III

The eleven chapters look scattered, but three shared disciplines bind them. Whichever chapter you read, noticing which of these threads it touches makes the whole easier to grasp.

Thread One: Materials Provided "On Request" Are Not Pushed

Congress presentation abstracts and proceedings, journal reprints, literature digests — these are provided only when a medical professional asks for them. They are not something a company hands out proactively. Why honor passivity this much? Such materials can contain presentation data whose medical evaluation is not yet settled, or a body of literature shaped by one company's selection. If a company forces them on someone who never asked, that turns from information provision into promotion.

So the brakes are placed not in "good intentions" but in numbers and structure: a ceiling on the number of copies, a ceiling on the distribution period, and, for Web posting, keeping the material independent of the product page, limiting access to the individual who requested it, refusing a setup where anyone can view it with a single Yes/No click, and not actively steering people to it by email. Passivity is secured operationally.

Thread Two: For Patients and the General Public, Disease Explanation Is the Rule

Disease-explanation materials and patient-facing materials reach the eyes of patients and the general public. Two dangers loom largest here. One is steering toward a specific drug; the other is leaving the impression of a confirmed diagnosis — "with these symptoms, I must have this disease."

So the rule is to stay with explaining the disease: name a drug only down to its therapeutic-class name, and present coping options fairly without tilting toward a particular drug. Self-check tools, too, must avoid the impression that symptoms alone settle a diagnosis, and should prompt consultation with a physician. Risk explanations, even when medically correct, are arranged so as not to breed the misunderstanding that one "will surely develop" or "will surely be cured." Lay readers read neither the package insert nor the review report. Precisely for that reason, the care of not letting a single presentation choice form a false picture weighs even more heavily here than in materials for professionals.

Thread Three: Lists and Comparisons Forbid Deliberate Omission

Materials that line up several products — product lists, compatibility tables — by their structure carve out a slice of the information, and so easily breed bias or a distorted picture of the whole. Quietly dropping an inconvenient product, blurring the selection criteria — such deliberate omission is the gravest risk.

So the guide requires either taking up all related drugs or taking up a product group selected by a clear standard, and it forbids any presentation that emphasizes a particular product or disparages competitors. Because the very act of lining things up carries the weight of comparison, what is included and what is left out must be fair.

The Three ThreadsChapters Chiefly AffectedWhat Is ProtectedTypical Deviation
On request / no pushingAbstract collections, reprints, literature digestsPassivity of information provisionDistribution to non-requesters; active Web steering
Disease explanation as the ruleDisease-explanation and patient-facing materialsThe judgment of patients and the publicSteering to a specific drug; impression of a confirmed diagnosis
No deliberate omissionProduct lists, compatibility tablesFairness of comparisonExcluding unfavorable products; hiding the selection standard

04A Map of the Eleven Chapters

Each chapter of Part III is arranged by medium and use. Here only the overall picture is shown; the details unfold on each chapter's page.

The sheer number of chapters is the flip side of Part III's difficulty. The more formless a material, the more you must descend into medium-specific detail to seal off the entry points of deviation. No single abstract principle can cover everything, so the work is split across eleven chapters to pin down the particulars.

05Part III Seen Through the Discipline of Science

Part III's materials span many media, but the honesty demanded of the information is continuous with Parts I and II. The hierarchy of evidence (meta-analysis and systematic review > randomized controlled trial > observational study > case report > expert opinion) remains the measuring stick here too. Congress abstracts and proceedings in particular mix in data that has not been peer-reviewed and whose evaluation is not yet settled. Hence the frame of passivity — "on request" — and of authorship under the company's own responsibility.

The design philosophy of sealing off "true but misleading" is tested most of all in Part III. A compatibility table states only the facts of physical-chemical change and avoids the evaluative word "compatible"; a product list may carry the unit drug price but not the daily drug cost or the patient's out-of-pocket share — both because the guide knows that a single choice of which facts to select and how to present them can breed a false impression. The asymmetric duty to disclose safety even when unfavorable takes concrete form in presentation materials as the rule to make safety stand out at least as prominently as efficacy.

In closing

Part III is the part that best shows the guide is not an answer key. Assuming that materials with no explicit text will surely appear, it sends the reader back to the "why" — the intent of the product information summary and the JPMA Code. This stance of showing a destination rather than a procedure is the foreword's spirit translated into operation.

Keep the three threads in mind — provide on request without pushing, keep patient-facing materials to disease explanation, do not deliberately omit in lists and comparisons — and you will rarely lose your way wherever you read among the eleven chapters. What governs formless materials is, in the end, not the letter of a clause but the purpose itself: convey accurately, and do not mislead.

Pages in this level